Viking Therapeutics Inc (VKTX)
79.55
+4.13
(+5.48%)
USD |
NASDAQ |
Apr 30, 16:00
79.60
+0.05
(+0.06%)
After-Hours: 16:31
Viking Therapeutics Cash from Investing (Quarterly): -459.79M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -459.79M |
| December 31, 2023 | 35.73M |
| September 30, 2023 | -12.53M |
| June 30, 2023 | -204.48M |
| March 31, 2023 | 2.198M |
| December 31, 2022 | 7.26M |
| September 30, 2022 | 26.89M |
| June 30, 2022 | 18.98M |
| March 31, 2022 | 1.619M |
| December 31, 2021 | 27.41M |
| September 30, 2021 | 13.62M |
| June 30, 2021 | 3.56M |
| March 31, 2021 | -6.627M |
| December 31, 2020 | 30.27M |
| September 30, 2020 | -9.634M |
| June 30, 2020 | 9.78M |
| March 31, 2020 | 11.15M |
| December 31, 2019 | -11.06M |
| September 30, 2019 | 15.15M |
| June 30, 2019 | 10.98M |
| Date | Value |
|---|---|
| March 31, 2019 | -7.609M |
| December 31, 2018 | -142.39M |
| September 30, 2018 | -27.09M |
| June 30, 2018 | -66.62M |
| March 31, 2018 | -29.63M |
| December 31, 2017 | -4.396M |
| September 30, 2017 | 1.392M |
| June 30, 2017 | -0.765M |
| March 31, 2017 | 2.039M |
| December 31, 2016 | 1.447M |
| September 30, 2016 | 0.441M |
| June 30, 2016 | -4.831M |
| March 31, 2016 | 5.973M |
| December 31, 2015 | 1.956M |
| September 30, 2015 | -3.252M |
| June 30, 2015 | -12.17M |
| March 31, 2015 | 0.00 |
| December 31, 2014 | |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-459.79M
Minimum
Mar 2024
35.73M
Maximum
Dec 2023
-24.48M
Average
8.52M
Median
Cash from Investing (Quarterly) Benchmarks
| Eli Lilly and Co | -2.924B |
| Pfizer Inc | -11.00B |
| Madrigal Pharmaceuticals Inc | -362.12M |
| Akero Therapeutics Inc | 12.79M |
| Terns Pharmaceuticals Inc | 47.23M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -6.134M |
| Cash from Financing (Quarterly) | 606.04M |
| Free Cash Flow | -54.87M |
| Free Cash Flow Per Share (Quarterly) | -0.0593 |
| Free Cash Flow Yield | -0.69% |